-
公开(公告)号：US20170283506A1
公开(公告)日：2017-10-05
申请号：US15620214
申请日：2017-06-12
发明人： Hisashi Narimatsu , Akira Togayachi , Yuzuru Ikehara , Hiroyuki Kaji , Atsushi Kuno , Takashi Ohkura , Hideki Matsuzaki , Yoshitoshi Hirao , Jun Iwaki , Minako Abe , Masaharu Nomura , Masayuki Noguchi
摘要： An object of the present invention is to develop and provide a lung cancer differential marker with which lung cancer can be diagnosed conveniently and highly sensitively without depending only on increase or decrease in protein expression level between cancer patients and healthy persons. Another object of the present invention is to develop and provide a glycan marker capable of distinguishing histological types of lung cancer. Of serum glycoproteins, glycopeptide and glycoprotein groups whose glycan structures were altered specifically in lung cancer cell culture supernatants were identified, and they are provided as lung cancer differential markers.
-
公开(公告)号：US10539576B2
公开(公告)日：2020-01-21
申请号：US15620214
申请日：2017-06-12
发明人： Hisashi Narimatsu , Akira Togayachi , Yuzuru Ikehara , Hiroyuki Kaji , Atsushi Kuno , Takashi Ohkura , Hideki Matsuzaki , Yoshitoshi Hirao , Jun Iwaki , Minako Abe , Masaharu Nomura , Masayuki Noguchi
IPC分类号： G01N33/574 , G01N33/68 , C07K14/47 , C07K16/28 , C07K16/30
摘要： An object of the present invention is to develop and provide a lung cancer differential marker with which lung cancer can be diagnosed conveniently and highly sensitively without depending only on increase or decrease in protein expression level between cancer patients and healthy persons. Another object of the present invention is to develop and provide a glycan marker capable of distinguishing histological types of lung cancer. Of serum glycoproteins, glycopeptide and glycoprotein groups whose glycan structures were altered specifically in lung cancer cell culture supernatants were identified, and they are provided as lung cancer differential markers.
-
公开(公告)号：US20150329602A1
公开(公告)日：2015-11-19
申请号：US14654223
申请日：2013-12-18
发明人： Takashi Sato , Yasunori Chiba , Hiroaki Tateno , Hiroyuki Kaji , Masanori Goto , Hisashi Narimatsu
CPC分类号： C07K14/42 , G01N33/5308 , G01N2333/42 , G01N2400/00
摘要： [Problem] The purpose of the present invention is to stably supply high-quality and highly uniform Wisteria floribunda agglutinin (WFA) that recognizes biologically important sugar-chain markers, to elucidate the sugar-chain recognition activity in detail, and to furthermore increase the specificity of the sugar-chain recognition activity. [Solution] The present invention involves the development of a technique for cloning genes for coding Wisteria floribunda agglutinin (WFA) and producing recombinant WFA having the same sugar-chain recognition activity as natural WFA from transformed bacteria. Natural WFA is reduced to thereby manufacture a reduced WFA monomer for specifically recognizing terminal GalNAc residue. A recombinant monomer WFA for recognizing LDN (GalNAcβ1, 4GlcNAc) sugar chain, which is important as a diagnostic marker among sugar chains having a terminal GalNAc residue, is manufactured by introducing cysteine mutation to recombinant WFA or by C-terminal-side amino acid deletion.
摘要翻译： [问题]本发明的目的是稳定地提供识别生物重要的糖链标记物的高品质和高度均匀的紫藤凝集素（WFA），以详细阐明糖链识别活性，并进一步增加 糖链识别活性的特异性。 [解决方案]本发明涉及开发克隆用于编码Wisteria floribunda凝集素（WFA）的基因的克隆技术，并且生产与来自转化细菌的天然WFA具有相同糖链识别活性的重组WFA。 减少天然WFA，从而制造用于特异性识别末端GalNAc残基的还原的WFA单体。 通过将半胱氨酸突变引入重组WFA或C末端侧氨基酸来制备重要单体WFA，其用于识别LDN（GalNAc＆bgr; 1,4GlcNAc）糖链，其作为具有末端GalNAc残基的糖链中的诊断标记是重要的 酸缺失。
-
4.发明授权公开(公告)号：US11571473B2
公开(公告)日：2023-02-07
申请号：US16972367
申请日：2019-06-06
发明人： Hisashi Narimatsu , Kiyohiko Angata , Hiroyuki Kaji , Atsushi Kuno , Takashi Sato , Yasunori Chiba , Akira Togayachi , Hiroki Shimizu , Maki Sogabe , Takanori Wagatsuma , Masashi Mizokami , Masaaki Korenaga , Kazuto Tajiri , Tatsuhiko Ozawa
IPC分类号： A61K39/29 , C07K14/005 , A61P31/20 , C07K16/08 , G01N33/576 , A61K39/00
摘要： An examination system that recognizes a glycosylated antigen in Dane particles of hepatitis B virus (HBV) and a neutralizing antibody that recognizes the glycosylated antigen and that exhibits an infection-inhibiting activity. It was elucidated that Dane particles are associated with specific glycan structures, and this enabled the construction of a new detection system for infectious, i.e., nucleic acid-containing, hepatitis B virus particles and the provision of a neutralizing antibody that recognizes a glycosylated antigen and that exhibits an infection-inhibiting activity.
-
公开(公告)号：US10358466B2
公开(公告)日：2019-07-23
申请号：US15706144
申请日：2017-09-15
发明人： Takashi Sato , Yasunori Chiba , Hiroaki Tateno , Hiroyuki Kaji , Masanori Goto , Hisashi Narimatsu
摘要： A Wisteria floribunda monomeric lectin polypeptide is provided. The Wisteria floribunda monomeric lectin polypeptide includes any one of the amino acid sequences selected from the group consisting of: (1) the amino acid sequence represented by SEQ ID NO: 2; (2) the amino acid sequence defined in (1) above, except that one to 20 amino acids at positions other than Cys272 position is/are deleted, substituted, inserted, or added; and (3) the amino acid sequence defined in (1) or (2) above, further having an N-terminus deletion of one to 30 amino acids, in which Cys272 is alkylated, and the polypeptide is capable of specifically binding to a GalNAc terminal sugar chain.
-
公开(公告)号：US20180134756A1
公开(公告)日：2018-05-17
申请号：US15706144
申请日：2017-09-15
发明人： Takashi Sato , Yasunori Chiba , Hiroaki Tateno , Hiroyuki Kaji , Masanori Goto , Hisashi Narimatsu
CPC分类号： C07K14/42 , G01N33/5308 , G01N2333/42 , G01N2400/00
摘要： A Wisteria floribunda monomeric lectin polypeptide is provided. The Wisteria floribunda monomeric lectin polypeptide includes any one of the amino acid sequences selected from the group consisting of: (1) the amino acid sequence represented by SEQ ID NO: 2; (2) the amino acid sequence defined in (1) above, except that one to 20 amino acids at positions other than Cys272 position is/are deleted, substituted, inserted, or added; and (3) the amino acid sequence defined in (1) or (2) above, further having an N-terminus deletion of one to 30 amino acids, in which Cys272 is alkylated, and the polypeptide is capable of specifically binding to a GalNAc terminal sugar chain.
-
公开(公告)号：US09796765B2
公开(公告)日：2017-10-24
申请号：US14654223
申请日：2013-12-18
发明人： Takashi Sato , Yasunori Chiba , Hiroaki Tateno , Hiroyuki Kaji , Masanori Goto , Hisashi Narimatsu
CPC分类号： C07K14/42 , G01N33/5308 , G01N2333/42 , G01N2400/00
摘要： [Problem] The purpose of the present invention is to stably supply high-quality and highly uniform Wisteria floribunda agglutinin (WFA) that recognizes biologically important sugar-chain markers, to elucidate the sugar-chain recognition activity in detail, and to furthermore increase the specificity of the sugar-chain recognition activity.[Solution] The present invention involves the development of a technique for cloning genes for coding Wisteria floribunda agglutinin (WFA) and producing recombinant WFA having the same sugar-chain recognition activity as natural WFA from transformed bacteria. Natural WFA is reduced to thereby manufacture a reduced WFA monomer for specifically recognizing terminal GalNAc residue. A recombinant monomer WFA for recognizing LDN (GalNAcβ1, 4GlcNAc) sugar chain, which is important as a diagnostic marker among sugar chains having a terminal GalNAc residue, is manufactured by introducing cysteine mutation to recombinant WFA or by C-terminal-side amino acid deletion.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.029 秒)
